We are live on ! Find out more
IMNP

Immune Pharmaceuticals Inc.
IMNP

Delisted

IMNP was delisted on the 25th of July, 2018.

Back to rankings

17 hedge funds and large institutions have $183K invested in Immune Pharmaceuticals Inc. in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

13% more funds holding

Funds holding: 15 → 17 (+2)

49% less capital invested

Capital invested by funds: $360K → $183K (-$177K)

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$46.1K
2
EDRH
Edmond de Rothschild Holding
Switzerland
+$41.1K
3
IP
Intellectus Partners
California
+$14.8K
4
Goldman Sachs
Goldman Sachs
New York
+$13.5K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$6.98K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$133K
2
UBS Group
UBS Group
Switzerland
-$34.2K
3
VF
Virtu Financial
New York
-$14K
4
JP Morgan Chase
JP Morgan Chase
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$48K -$133K -278,677 -67%
Barclays
2
Barclays
United Kingdom
$34K +$46.1K +96,788 New
EDRH
3
Edmond de Rothschild Holding
Switzerland
$30K +$41.1K +86,325 New
CS
4
Credit Suisse
Switzerland
$11K +$4.71K +9,895 +42%
IP
5
Intellectus Partners
California
$11K +$14.8K +31,082 New
Goldman Sachs
6
Goldman Sachs
New York
$10K +$13.5K +28,405 New
Bank of America
7
Bank of America
North Carolina
$8K +$914 +1,920 +9%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$7K – – –
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Quebec, Canada
$6.3K +$5.24K +11,000 +157%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$6K +$1.24K +2,607 +18%
UBS Group
11
UBS Group
Switzerland
$5K -$34.2K -71,866 -82%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$5K +$6.98K +14,670 New
AG
13
Advisor Group
Arizona
$1K – – –
Morgan Stanley
14
Morgan Stanley
New York
$1K +$1.28K +2,695 +4,991%
VF
15
Virtu Financial
New York
– -$14K -24,681 Closed
JP Morgan Chase
16
JP Morgan Chase
New York
– -$7K -11,510 Closed

IMNP Hedge Fund Activity: Q1 2018 in Review

17 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q1 2018, worth a combined $183K — down 49% from $360K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IMNP positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Barclays, opening a new position worth an estimated $46.1K. The largest seller was Vanguard Group, cutting an estimated $133K.

  • 17 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q1 2018, up from 15 in Q4 2017.
  • Funds reported $183K of Immune Pharmaceuticals Inc. stock for Q1 2018, down 49% quarter-over-quarter.
  • 5 funds opened new Immune Pharmaceuticals Inc. positions in Q1 2018 and 3 closed out, a net change of +2 holders.
  • The largest Immune Pharmaceuticals Inc. buyer in Q1 2018 was Barclays, an estimated $46.1K added.
  • The largest Immune Pharmaceuticals Inc. seller in Q1 2018 was Vanguard Group, an estimated $133K sold.

Based on aggregated 13F filings for Q1 2018.